Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cingulate Inc.CING · Entity 6983 | Director | June 15, 2023 | June 20, 2023 |
| TREVENA INCTRVN · Entity 85383 | CLCO; SVP, Regulatory Affairs | February 10, 2021 | February 12, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cingulate Inc.
Report date June 15, 2023 · Filed June 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.98 · Expires 2033-06-15 | Direct | 15,000 |
Reported balance
After 2023-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-15 · Grant · Acquired 15,000 · Balance 15,000 F1: The option vests on the one-year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the one-year anniversary of the date of grant.
TREVENA INC
Report date February 10, 2021 · Filed February 12, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 344,022 |
Reported balance
After 2021-02-10 transaction · row 1
1 source rowRow 1 · 2021-02-10 · Tax withholding · Disposed 21,178 · Balance 344,022 F1: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of the restricted stock units. F2: These are shares withheld in connection with the non-reportable vesting and settlement of restricted stock units granted on February 10, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of the restricted stock units.
F2: These are shares withheld in connection with the non-reportable vesting and settlement of restricted stock units granted on February 10, 2020.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Vitae Pharmaceuticals, Inc
Report date October 25, 2016 · Filed October 25, 2016
Section 16 reporting ended · disclosed 2016-10-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.75 · Expires 2026-08-09 | Direct | 0 |
Reported balance
After 2016-10-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-10-25 · Disposition to issuer · Disposed 150,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F2: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on August 10, 2017 (the "Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option.
F2: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on August 10, 2017 (the "Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2023 Filed Jun 20, 2023 11:00 UTC | Cingulate Inc. CING · Entity 6983 | GrantStock Option (right to Buy) · Derivative | 15,000 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001493152-23-021771 · ownership.xml · derivative · entry 1 Applebaum Scott · CIK 0001618945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-06-15 F1 · derivative.exercise_date: The option vests on the one-year anniversary of the date of grant. Read SEC document |
| August 09, 2022 Filed Aug 11, 2022 21:05 UTC | Cingulate Inc. CING · Entity 6983 | GrantStock Option (right to Buy) · Derivative | 12,000 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001493152-22-022131 · ownership.xml · derivative · entry 1 Applebaum Scott · CIK 0001618945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2032-08-09 F1 · derivative.exercise_date: The option vests on the one-year anniversary of the date of grant. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 16:17 UTC | TREVENA INC TRVN · Entity 85383 | Tax withholdingCommon Stock | 21,178 | $2.85 | $60,357.30 |
DisclosureSEC source: 0001192482-21-000152 · edgar.xml · nonDerivative · entry 1 Applebaum Scott · CIK 0001618945 · CLCO; SVP, Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,022 F1 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of the restricted stock units. F2 · shares: These are shares withheld in connection with the non-reportable vesting and settlement of restricted stock units granted on February 10, 2020. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 19:44 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 172,750 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001192482-20-000830 · edgar.xml · derivative · entry 2 Applebaum Scott · CIK 0001618945 · CLCO; SVP, Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,750 Underlying: Common Stock · 172,750 shares Expires 2030-12-17 F2 · derivative.exercise_date: The option shall vest and become exercisable with respect to one-sixteenth of the total number of shares subject to the option on a quarterly basis (every three months) from the Transaction Date listed above, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of each such vesting date. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 19:44 UTC | TREVENA INC TRVN · Entity 85383 | GrantCommon Stock | 115,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-20-000830 · edgar.xml · nonDerivative · entry 1 Applebaum Scott · CIK 0001618945 · CLCO; SVP, Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,200 F1 · shares: These shares are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock of the Issuer. The shares underlying the RSUs shall vest in four (4) equal annual installments on each of December 17, 2021, December 17, 2022, December 17, 2023 and December 17, 2024, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan, as amended (the "Plan")) as of each such vesting date. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 16:50 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001209191-20-008794 · doc4.xml · derivative · entry 2 Applebaum Scott · CIK 0001618945 · CLCO; SVP Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-02-10 F2 · derivative.exercise_date: The option shall vest and become exercisable with respect to one-sixteenth of the total number of shares subject to the option on a quarterly basis (every three months) from the Transaction Date listed above, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of each such vesting date. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 16:50 UTC | TREVENA INC TRVN · Entity 85383 | GrantCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-008794 · doc4.xml · nonDerivative · entry 1 Applebaum Scott · CIK 0001618945 · CLCO; SVP Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 F1 · shares: These shares are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock of the Issuer. The shares underlying the RSUs shall vest in four (4) equal annual installments on each of February 10, 2021, February 10, 2022, February 10, 2023 and February 10, 2024, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan, as amended (the "Plan")) as of each such vesting date. Read SEC document |
| October 25, 2016 Filed Oct 25, 2016 16:30 UTC | Vitae Pharmaceuticals, Inc VTAE · Entity 181526 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $12.25 Strike: $8.75 | $1,837,500.00 |
DisclosureSEC source: 0001104659-16-151937 · a4.xml · derivative · entry 1 Applebaum Scott · CIK 0001618945 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2026-08-09 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F2 · derivative.exercise_date: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on August 10, 2017 (the "Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.